FATE THERAPEUTICS WKN: A1W50M ISIN: US31189P1021 Kürzel: FATE Forum: Aktien Thema: Hauptdiskussion

ich hab keine Ahnung. aber hoffen kann man ja. Wenn es so weiter geht warum nicht? In 2-3 Jahren ???

25 Euro? Meinst das ist realistisch? Wieso zieht es die letzten Wochen so an?

ja hoffe mittelfristig auf 25 Euro

Weiter so..

👍

😎

Geht wieder hoch…

Hoffen wir es.. ansonsten durchhalten und eventuell nachkaufen..:-)

Ja leider. Mal sehen ob wieder hoch geht.

😁

Absturz

Ich habe genug.. aber okay..

Ja kaufen wir immer nach....

Thelen ist raus. Seitdem geht's ab

SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update. In order to participate in the conference call, please register using the conference link here. The live webcast can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com. Contact: Christina Tartaglia Stern Investor Relations, Inc. 212-362-1200 christina.tartaglia@sternir.com

Ich bin mit buyin 6,XX angestiegen, dann auf einmal 80% minus und habe dann zum Glück kräftig nachgekauft .. jetzt sehr sehr gut im Plus.. kann morgen aber schon wieder anders aussehen..